Biologists take tentative steps towards bespoke cancer drugs.
David
D
Cyranoski
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000077156:Gefitinib; D020869:Gene Expression Profiling; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D010597:Pharmacogenetics / Q000639:trends*; D011014:Pneumonia / Q000139:chemically induced / Q000235:genetics; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D011799:Quinazolines; D011505:Protein-Tyrosine Kinases; D000077156:Gefitinib